

Lattice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial

NCT07000162

Status	RECRUITING
Phase	Phase 2
Sponsor	Azienda USL Reggio Emilia - IRCCS
Enrollment	56 participants

Key Eligibility Criteria

Inclusion (13)

- Age ≥ 18 on day signing informed consent
- Histologically or cytologically confirmed cancer.
- Performance status of 0-2 on the ECOG Performance Scale.
- Advanced or locally advanced disease, not eligible for curative-intent treatment.
- Life expectancy > 6 months.

... and 8 more (see full listing online)

Exclusion (4)

- Additional malignancy that is progressing or requires active treatment. Exceptions include basal and squamous cell carcinoma of the skin or in situ cervical
- Currently participating in or has participated in a study of an investigational agent or using an investigational device within 2 weeks of the start of LRT.
- Prior high-dose radiotherapy overlapping with any planned site of protocol radiotherapy, if the dose overlap is > 10 Gy or is determined not safe by the treating physician.
- HIV patients with CD4+ T-cell counts < 350 cells/mcL or with a history of AIDS-defining opportunistic infection, within the 12 months prior to registration

Locations (1 total)

Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy, Italy